ATTORNEY DOCKET: AVSI-0033 (108328.00170) Patent Application

In the Claims:

WHAT IS CLAIMED:

1. (Currently Amended) A method for decreasing an involuntary cull in farm animals comprising:

- (a) penetrating a muscle tissue in the farm animals with a plurality of needle electrodes, wherein the plurality of needle electrodes are arranged in a spaced relationship;
- (b) introducing an isolated nucleic acid expression construct that encodes a growth-hormone-releasing-hormone ("GHRH") into the muscle tissue between the plurality of needle electrodes, wherein the encoded GHRH has at least 95% identical to (SEQ ID NO.: 1) has a sequence of SEQ ID NO.: 6 and is capable of binding to a GHRH receptor; and
- (c) applying a constant current electrical pulse to the plurality of needle electrodes, wherein the constant current electrical pulse is maintained under a threshold to allow a user to reduce cell heating and create less cell death;

wherein, the isolated nucleic acid expression construct comprises a synthetic muscle specific promoter; a nucleotide sequence capable of expressing the <u>encoded</u> GHRH molecule having at least 95% identical to (SEQ ID NO.: 1) having a sequence of SEQ ID NO.: 1; and a 3' untranslated region that are in an operatively positioned arrangement capable of expressing the encoded GHRH molecule under conditions that promote expression of the nucleotide sequence in the muscle tissue, wherein the involuntary cull comprises infection, disease, morbidity, or mortality of the farm animals; and wherein the farm animals comprises ruminant animals, food animals, or work animals.

- 2. (Previously Amended) The method of claim 1, wherein the involuntary cull from mortality is decreased from about 20% in farm animals not having the isolated nucleic acid expression construct delivered into muscle cells to less than 15% in farm animals having the isolated nucleic acid expression construct delivered.
- 3. (Original) The method of claim 1, wherein the involuntary cull comprises mortality at birth of newborns of the farm animals.
- 4. (Original) The method of claim 1, wherein the involuntary cull comprises post-natal mortality of newborns of the farm animals.
- 5. (Canceled)
- 6. (Canceled)
- 7. (Original) The method of claim 1, wherein the isolated nucleic acid expression construct is delivered in a single dose.
- 8. (Original) The method of claim 7, wherein the single dose comprises about a 2mg quantity of nucleic acid expression construct.
- 9. (Previously Amended) The method of claim 1, wherein the muscle cells of the farm animals comprise diploid cells.
- 10. (Canceled)
- 11. (Previously Amended) The method of claim 1, wherein the isolated nucleic acid expression construct comprises SEQID No.: 11.
- 12. (Withdrawn) The method of claim 1, wherein the isolated nucleic acid expression construct comprises an optimized pAV0204 bGHRH plasmid (SEQID#19).

- 13. (Withdrawn) The method of claim 1, wherein the isolated nucleic acid expression construct is a TI-GHRH plasmid (SEQID#12), TV-GHRH Plasmid (SEQID#13), 15/27/28 GHRH plasmid (SEQID#14), or pSP-wt-GHRH plasmid.
- 14. (Withdrawn) The method of claim 1, wherein the isolated nucleic acid expression construct is an optimized pAV0202 mGHRH plasmid (SEQID#17), pAV0203 rGHRH plasmid (SEQID#18), pAV0205 oGHRH plasmid (SEQID#20), pAV0206 cGHRH plasmid (SEQID#21), or pAV0207 pGHRH plasmid (SEQID#28).
- 15. (Original) The method of claim 1, wherein the isolated nucleic acid expression construct further comprises, a transfection-facilitating polypeptide.
- 16. (Original) The method of claim 15, wherein the transfection-facilitating polypeptide comprises a charged polypeptide.
- 17. (Original) The method of claim 15, wherein the transfection-facilitating polypeptide comprises poly-L-glutamate.
- 18. (Original) The method of claim 1, wherein the delivering into the cells of the farm animals the isolated nucleic acid expression construct initiates expression of the encoded GHRH or functional biological equivalent thereof.
- 19. (Original) The method of claim 1, wherein the encoded GHRH is a biologically active polypeptide; and the encoded functional biological equivalent of GHRH is a polypeptide that has been engineered to contain a distinct amino acid sequence while simultaneously having similar or improved biologically activity when compared to the GHRH polypeptide.
- 20. (Canceled)
- 21. (Canceled)

Patent Application

- 22. (Original) The method of claim 1, wherein the farm animals comprise dairy cows.
- 23. (Currently Amended) A method for improving a body condition score ("BCS") in farm animals comprising:
 - (a) penetrating a muscle tissue in the farm animals with a plurality of needle electrodes, wherein the plurality of needle electrodes are arranged in a spaced relationship;
 - (b) introducing an isolated nucleic acid expression construct that encodes a growth-hormone-releasing-hormone ("GHRH") into the muscle tissue between the plurality of needle electrodes, wherein the encoded GHRH has at least 95% identical to (SEQ ID NO.: 1) has a sequence of SEQ ID NO.: 6 and is capable of binding to a GHRH receptor; and
 - (c) applying a constant current electrical pulse to the plurality of needle electrodes, wherein the constant current electrical pulse is maintained under a threshold to allow one to reduce cell heating and create less cell death;

wherein, the isolated nucleic acid expression construct comprises a synthetic muscle specific promoter; a nucleotide sequence capable of expressing the encoded GHRH molecule having at least 95% identical to (SEQ ID NO.: 1) has a sequence of SEQ ID NO.: 1; and a 3' untranslated region that are in an operatively positioned arrangement capable of expressing the encoded GHRH molecule under conditions that promote expression of the nucleotide sequence in the muscle tissue, wherein the BSC BCS is an aid used to evaluate an overall nutritional state of the farm animals; and wherein the farm animals comprises ruminant animals, food animals, or work animals.

- 24. (Canceled)
- 25. (Canceled)

- 26. (Original) The method of claim 23, wherein the isolated nucleic acid expression construct is delivered in a single dose.
- 27. (Original) The method of claim 26, wherein the single dose comprises about a 2mg quantity of nucleic acid expression construct.
- 28. (Currently Amended) The method of claim 26 23, wherein the muscle cells of the farm animals comprise diploid cells.
- 29. (Canceled)
- 30. (Currently Amended) The method of claim 26 23, wherein the isolated nucleic acid expression construct comprises SEQID SEQ ID No.: 11.
- 31. (Withdrawn) The method of claim 26, wherein the isolated nucleic acid expression construct comprises an optimized pAV0204 bGHRH plasmid (SEQID#19).
- 32. (Withdrawn) The method of claim 26, wherein the isolated nucleic acid expression construct is a TI-GHRH plasmid (SEQID#12), TV-GHRH Plasmid (SEQID#13), 15/27/28 GHRH plasmid (SEQID#14), or pSP-wt-GHRH plasmid.
- 33. (Withdrawn) The method of claim 26, wherein the isolated nucleic acid expression construct is an optimized pAV0202 mGHRH plasmid (SEQID#17), pAV0203 rGHRH plasmid (SEQID#18), pAV0205 oGHRH plasmid (SEQID#20), pAV0206 cGHRH plasmid (SEQID#21), or pAV0207 pGHRH plasmid (SEQID#28).
- 34. (Currently Amended) The method of claim 26 23, wherein the isolated nucleic acid expression construct further comprises, a transfection-facilitating polypeptide.
- 35. (Original) The method of claim 34, wherein the transfection-facilitating polypeptide comprises a charged polypeptide.

- 36. (Original) The method of claim 34, wherein the transfection-facilitating polypeptide comprises poly-L-glutamate.
- 37. (Currently Amended) The method of claim 26 23, wherein the delivering into the cells of the farm animals the isolated nucleic acid expression construct initiates expression of the encoded GHRH or functional biological equivalent thereof.
- 38. (Currently Amended) The method of claim 26 23, wherein the encoded GHRH is a biologically active polypeptide; and the encoded functional biological equivalent of GHRH is a polypeptide that has been engineered to contain a distinct amino acid sequence while simultaneously having similar or improved biologically activity when compared to the GHRH polypeptide.
- 39. (Canceled)
- 40. (Currently Amended) The method of claim 26 23, wherein the farm animals comprises a ruminant animals, a food animals, or a work animals.
- 41. (Currently Amended) The method of claim 26 23, wherein the farm animals comprises a pig, sheep, goat or chicken.
- 42. (Currently Amended) The method of claim 26 23, wherein the farm animals comprise bovine.
- 43. (Previously Amended) The method of claim 42, wherein the farm animals comprise dairy cows.
- 44. (Currently Amended) A method for increasing milk production in a dairy cow comprising:
 - (d) penetrating a muscle tissue in the dairy cow with a plurality of needle electrodes, wherein the plurality of needle electrodes are arranged in a spaced relationship;

- (e) introducing a single dose of an isolated nucleic acid expression construct that encodes a growth-hormone-releasing-hormone ("GHRH") into the muscle tissue between the plurality of needle electrodes, wherein the encoded GHRH has at least 95% identical to (SEQ ID NO.:-1) has a sequence of SEQ ID NO.: 6 and is capable of binding to a GHRH receptor; and
- (f) applying a constant current electrical pulse to the plurality of needle electrodes, wherein the constant current electrical pulse is maintained under a threshold to allow one to reduce cell heating and create less cell death;

wherein, the isolated nucleic acid expression construct comprises a synthetic muscle specific promoter; a nucleotide sequence capable of expressing the <u>encoded</u> GHRH molecule having at least 95% identical to (SEQ ID NO.: 1)has a sequence of SEQ ID NO.: 1; and a 3' untranslated region that are in an operatively positioned arrangement capable of expressing the encoded GHRH molecule under conditions that promote expression of the nucleotide sequence in the muscle tissue.

- 45. (Original) The method of claim 44, wherein the increase in milk production is increased from about 8% to about 18% in farm animals having the isolated nucleic acid expression construct delivered when compared to animals not having the isolated nucleic acid expression construct delivered.
- 46. (Canceled)
- 47. (Original) The method of claim 44, wherein the single dose comprises about a 2mg quantity of nucleic acid expression construct.
- 48. (Currently Amended) The method of claim 44, wherein the isolated nucleic acid expression construct comprises SEQID SEQ ID No.: 11.

- 49. (Withdrawn) The method of claim 44, wherein the isolated nucleic acid expression construct comprises an optimized pAV0204 bGHRH plasmid (SEQID#19).
- 50. (Withdrawn) The method of claim 44, wherein the isolated nucleic acid expression construct is a TI-GHRH plasmid (SEQID#12), TV-GHRH Plasmid (SEQID#13), 15/27/28 GHRH plasmid (SEQID#14), or pSP-wt-GHRH plasmid.
- 51. (Withdrawn) The method of claim 44, wherein the isolated nucleic acid expression construct is an optimized pAV0202 mGHRH plasmid (SEQID#17), pAV0203 rGHRH plasmid (SEQID#18), pAV0205 oGHRH plasmid (SEQID#20), pAV0206 cGHRH plasmid (SEQID#21), or pAV0207 pGHRH plasmid (SEQID#28).
- 52. (Original) The method of claim 44, wherein the isolated nucleic acid expression construct further comprises, a transfection-facilitating polypeptide.
- 53. (Original) The method of claim 52, wherein the transfection-facilitating polypeptide comprises a charged polypeptide.
- 54. (Original) The method of claim 52, wherein the transfection-facilitating polypeptide comprises poly-L-glutamate.
- 55. (Original) The method of claim 44, wherein the delivering into the cells of the farm animals the isolated nucleic acid expression construct initiates expression of the encoded GHRH or functional biological equivalent thereof.
- 56. (Original) The method of claim 44, wherein the encoded GHRH is a biologically active polypeptide; and the encoded functional biological equivalent of GHRH is a polypeptide that has been engineered to contain a distinct amino acid sequence while simultaneously having similar or improved biologically activity when compared to the GHRH polypeptide.

ATTO.	RNEY DOCKET: AVSI-0033 (108328.00170)	Patent Application
57.	(Canceled)	
58.	(Canceled)	
59.	(Canceled)	
60.	(Canceled)	
61.	(Canceled)	
62.	(Canceled)	
63.	(Withdrawn) The method of claim 58, wherein the isolated construct is a TI-GHRH plasmid (SEQID#12), TV-GHRH 15/27/28 GHRH plasmid (SEQID#14), pSP-wt-GHRH plasmid (SEQID#17), pAV0203 rGHRH plasmid (SEQID# plasmid (SEQID#20), pAV0206 cGHRH plasmid (SEQID#21 plasmid (SEQID#28).	Plasmid (SEQID#13), nid, pAV0202 mGHRH 18), pAV0205 oGHRH
64.	(Canceled)	
65.	(Canceled)	
66.	(Canceled)	
67.	(Canceled)	
68.	(Canceled)	

- 69. (Withdrawn) The method of claim 66, wherein the isolated nucleic acid expression construct is a TI-GHRH plasmid (SEQID#12), TV-GHRH Plasmid (SEQID#13), 15/27/28 GHRH plasmid (SEQID#14), pSP-wt-GHRH plasmid, pAV0202 mGHRH plasmid (SEQID#17), pAV0203 rGHRH plasmid (SEQID#18), pAV0205 oGHRH plasmid (SEQID#20), pAV0206 cGHRH plasmid (SEQID#21), or pAV0207 pGHRH plasmid (SEQID#28).
- 70. (Canceled)
- 71. (Canceled)
- 72. (Canceled)
- 73. (Canceled)
- 74. (Canceled)
- 75. (Withdrawn) The method of claim 72, wherein the isolated nucleic acid expression construct is a TI-GHRH plasmid (SEQID#12), TV-GHRH Plasmid (SEQID#13), 15/27/28 GHRH plasmid (SEQID#14), pSP-wt-GHRH plasmid, pAV0202 mGHRH plasmid (SEQID#17), pAV0203 rGHRH plasmid (SEQID#18), pAV0205 oGHRH plasmid (SEQID#20), pAV0206 cGHRH plasmid (SEQID#21), or pAV0207 pGHRH plasmid (SEQID#28).
- 76. (Canceled)

- 77. (Withdrawn) A method of decreasing an involuntary cull in a farm animal comprising: delivering into the farm animal an isolated a growth hormone secretagogue molecule; wherein the involuntary cull comprises infection, disease, morbidity, or mortality of the farm animal; wherein the isolated growth hormone secretagogue molecule facilitates growth hormone ("GH") secretion in the farm animal; the farm animal comprises a ruminant animal, a food animal, or a work animal; and wherein the growth hormone secretagogue comprises an isolated biologically active polypeptide generated from a recombinant nucleic acid expression construct that encodes a growth hormone releasing hormone ("GHRH") or functional biological equivalent thereof.
- 78. (Canceled)
- 79. (Withdrawn) The method of claim 77, wherein the involuntary cull comprises mortality at birth of newborns of the farm animals.
- 80. (Withdrawn) The method of claim 77, wherein the involuntary cull comprises post-natal mortality of newborns of the farm animals.
- 81. (Canceled)
- 82. (Canceled)
- 83. (Canceled)
- 84. (Canceled)
- 85. (Canceled)
- 86. (Withdrawn) The method of claim 81, wherein isolated biologically active polypeptide generated from the recombinant nucleic acid expression construct that encodes the GHRH or functional biological equivalent thereof is of formula (SEQID No: 6):

-X₁-X₂-DAIFTNSYRKVL-X₃-QLSARKLLQDI-X₄-X₅-RQQGERNQEQGA-OH

wherein the formula has the following characteristics:

X₁ is a D-or L-isomer of the amino acid tyrosine ("Y"), or histidine ("H");

X₂ is a D-or L-isomer of the amino acid alanine ("A"), valine ("V"), or isoleucine ("I");

X₃ is a D-or L-isomer of the amino acid alanine ("A") or glycine ("G");

X4 is a D-or L-isomer of the amino acid methionine ("M"), or leucine ("L");

 X_5 is a D-or L-isomer of the amino acid serine ("S") or asparagine ("N"); or a combination thereof.

- 87. (Canceled)
- 88. (Canceled)
- 89. (Withdrawn) A method of improving a body condition score ("BCS") in farm animals comprising: delivering into the farm animal an isolated a growth hormone secretagogue molecule; wherein the BSC is an aid used to evaluate an overall nutritional state of the farm animal; wherein the isolated growth hormone secretagogue molecule facilitates growth hormone ("GH") secretion in the farm animal; the farm animal comprises a ruminant animal, a food animal, or a work animal; and wherein the growth hormone secretagogue comprises an isolated biologically active polypeptide generated from a recombinant nucleic acid expression construct that encodes a growth hormone releasing hormone ("GHRH") or functional biological equivalent thereof.
- 90. (Canceled)
- 91. (Canceled)
- 92. (Canceled)
- 93. (Canceled)

- 94. (Canceled)
- 95. (Canceled)
- 96. (Canceled)
- 97. (Withdrawn) The method of claim 93, wherein the isolated biologically active polypeptide generated from the recombinant nucleic acid expression construct that encodes the GHRH or functional biological equivalent thereof is of formula (SEQID No: 6):
 - -X₋₁-X₂-DAIFTNSYRKVL-X₃-QLSARKLLQDI-X₄-X₅-RQQGERNQEQGA-OH

wherein the formula has the following characteristics:

X₁ is a D-or L-isomer of the amino acid tyrosine ("Y"), or histidine ("H");

 X_2 is a D-or L-isomer of the amino acid alanine ("A"), valine ("V"), or isoleucine ("I");

X₃ is a D-or L-isomer of the amino acid alanine ("A") or glycine ("G");

 X_4 is a D-or L-isomer of the amino acid methionine ("M"), or leucine ("L");

X₅ is a D-or L-isomer of the amino acid serine ("S") or asparagine ("N");

or a combination thereof.

- 98. (Canceled)
- 99. (Withdrawn) The method of claim 89, wherein the farm animal comprise a dairy cow.